ArticleHaematologica2018
Safety and efficacy of plerixafor dose escalation for the mobilization of CD34
Article in Haematologica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial.Nature medicine · 2023Trial
- Evidence for continued dose escalation of plerixafor for hematopoietic progenitor cell collections in sickle cell disease.Blood cells, molecules & diseases · 2021Trial
- GroβT rapidly and reliably mobilizes primitive hematopoietic stem and progenitor cells in nonhuman primates.Molecular therapy. Methods & clinical development · 2025Article
- Emerging Gene Therapies in Sickle Cell Disease: A Comparative Review of Efficacy and Safety Against Standard Treatments.Journal of blood medicine · 2025Review
- Article
- Effect of voxelotor on murine bone marrow and peripheral blood with hematopoietic progenitor cell mobilization for gene therapy of sickle cell disease.Blood cells, molecules & diseases · 2024Article
- Gene therapy for sickle cell disease.Hematology. American Society of Hematology. Education Program · 2023Article
- Effective therapies for sickle cell disease: are we there yet?Trends in genetics : TIG · 2022Review
- Debating the Future of Sickle Cell Disease Curative Therapy: Haploidentical Hematopoietic Stem Cell Transplantation vs. Gene Therapy.Journal of clinical medicine · 2022Article
- Evolution of Gene Therapy, Historical Perspective.Hematology/oncology clinics of North America · 2022Review
- Editing outside the body: Ex vivo gene-modification for β-hemoglobinopathy cellular therapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2021Review
- Impact of a grant program to spur advances in sickle cell disease research.Blood advances · 2021Article
- Process and procedural adjustments to improve CD34+ collection efficiency of hematopoietic progenitor cell collections in sickle cell disease.Transfusion · 2021Article
- Research in Sickle Cell Disease: From Bedside to Bench to Bedside.HemaSphere · 2021Review
- Disease severity impacts plerixafor-mobilized stem cell collection in patients with sickle cell disease.Blood advances · 2021Article
- Getting blood out of a stone: Identification and management of patients with poor hematopoietic cell mobilization.Blood reviews · 2021Review
- Genetic therapies for the first molecular disease.The Journal of clinical investigation · 2021Review
- Transfusion and Cellular Therapy in Pediatric Sickle Cell Disease.Clinics in laboratory medicine · 2021Review
- Parameters affecting successful stem cell collections for genetic therapies in sickle cell disease.Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2021Review
- Gene Therapy of the Hemoglobinopathies.HemaSphere · 2020Review
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
14 authors.
Funding
Abstract
Gene therapy for sickle cell disease is limited by the yield of hematopoietic progenitor cells that can be harvested for transduction or gene editing. We therefore performed a phase I dose-escalation study of the hematopoietic progenitor cell mobilizing agent plerixafor to evaluate the efficacy and safety of standard dosing on peripheral blood CD34
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.